Prilocaine


Amide local anesthetic (intermediate-acting, low-toxicity)

An amide local anesthetic with the lowest systemic toxicity in the class but the dose-dependent risk of methemoglobinemia from o-toluidine metabolite generation.

Abstract

Prilocaine (N-(2-methylphenyl)-2-(propylamino)propanamide; CAS 721-50-6; molecular formula C13H20N2O; molecular weight 220.31) is an amide local anesthetic developed at AB Astra in the late 1950s and introduced clinically in the 1960s (Citanest). The compound has the lowest systemic toxicity in the amide class (CNS and cardiac toxic doses higher than lidocaine, mepivacaine, or bupivacaine on a milligram-per-kilogram basis), reflecting rapid hepatic clearance and high tissue redistribution. Prilocaine is the principal component of the EMLA cream alongside lidocaine, where the eutectic mixture of the two oils provides effective topical anesthesia of intact skin for venipuncture and minor superficial procedures. The principal clinical limitation is dose-dependent methemoglobinemia: prilocaine is hydrolyzed in the liver to o-toluidine, which is hydroxylated to a methemoglobin-generating metabolite. The risk is amplified in patients with G6PD deficiency, NADH-methemoglobin reductase deficiency, or concurrent administration of other oxidant drugs (dapsone, sulfamethoxazole, benzocaine). Mechanism is the standard amide voltage-gated sodium channel block. Onset and duration are intermediate (similar to lidocaine and mepivacaine). Prilocaine is widely used in dental anesthesia in Europe and Asia and is the principal component of dental cartridges in several markets.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph